Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schecter

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2024
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion StudyMaria-Victoria Mateos, Katja Weisel, Joris Diels, et al.
Journal of Comparative Effectiveness Research|August 20, 2024
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weightingWinfried Alsdorf, Joris Diels, Francesca Ghilotti, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare DatabaseBinod Dhakal, Jinghua He, Jordan M Schecter, et al.
Blood Advances|August 7, 2024
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron databaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|February 23, 2022
Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma TherapyMathieu Marella, Xiang Yao, Vinicius Carreira, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaAndrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
Cancer Reports (Hoboken, N.J.)|February 15, 2022
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapiesRebecca Crawford, Katharine S Gries, Satish Valluri, et al.
Current Medical Research and Opinion|August 12, 2024
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparisonNoffar Bar, Joris Diels, Suzy van Sanden, et al.
Advances in Therapy|July 4, 2025
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment WeightingRafael Fonseca, Joris Diels, Francesca Ghilotti, et al.
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2024
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion StudyMaria-Victoria Mateos, Katja Weisel, Joris Diels, et al.
Journal of Comparative Effectiveness Research|August 20, 2024
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weightingWinfried Alsdorf, Joris Diels, Francesca Ghilotti, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare DatabaseBinod Dhakal, Jinghua He, Jordan M Schecter, et al.
Blood Advances|August 7, 2024
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron databaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|February 23, 2022
Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma TherapyMathieu Marella, Xiang Yao, Vinicius Carreira, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaAndrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
Cancer Reports (Hoboken, N.J.)|February 15, 2022
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapiesRebecca Crawford, Katharine S Gries, Satish Valluri, et al.
Current Medical Research and Opinion|August 12, 2024
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparisonNoffar Bar, Joris Diels, Suzy van Sanden, et al.
Advances in Therapy|July 4, 2025
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment WeightingRafael Fonseca, Joris Diels, Francesca Ghilotti, et al.
Pageof 8